Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101


Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor.

Barok M, Balázs M, Nagy P, Rákosy Z, Treszl A, Tóth E, Juhász I, Park JW, Isola J, Vereb G, Szöllosi J.

Cancer Lett. 2008 Feb 18;260(1-2):198-208. Epub 2007 Dec 21.


Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance.

Barok M, Isola J, Pályi-Krekk Z, Nagy P, Juhász I, Vereb G, Kauraniemi P, Kapanen A, Tanner M, Vereb G, Szöllösi J.

Mol Cancer Ther. 2007 Jul;6(7):2065-72.


Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing.

Kute TE, Savage L, Stehle JR Jr, Kim-Shapiro JW, Blanks MJ, Wood J, Vaughn JP.

Cancer Immunol Immunother. 2009 Nov;58(11):1887-96. doi: 10.1007/s00262-009-0700-0. Epub 2009 Apr 2.


Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.

Barok M, Tanner M, Köninki K, Isola J.

Breast Cancer Res. 2011 Apr 21;13(2):R46. doi: 10.1186/bcr2868.


HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.

Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F.

Breast Cancer Res Treat. 2011 Nov;130(1):29-40. doi: 10.1007/s10549-010-1281-5. Epub 2010 Dec 9.


Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.

Zsebik B, Citri A, Isola J, Yarden Y, Szöllosi J, Vereb G.

Immunol Lett. 2006 Apr 15;104(1-2):146-55. Epub 2005 Dec 12.


Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).

Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castilló B, Pérez-Martínez MC, Cufí S, Del Barco S, Bernado L, Brunet J, López-Bonet E, Menendez JA.

Int J Oncol. 2010 Sep;37(3):669-78.


Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.

Reim F, Dombrowski Y, Ritter C, Buttmann M, Häusler S, Ossadnik M, Krockenberger M, Beier D, Beier CP, Dietl J, Becker JC, Hönig A, Wischhusen J.

Cancer Res. 2009 Oct 15;69(20):8058-66. doi: 10.1158/0008-5472.CAN-09-0834. Epub 2009 Oct 13.


Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer.

Bozionellou V, Mavroudis D, Perraki M, Papadopoulos S, Apostolaki S, Stathopoulos E, Stathopoulou A, Lianidou E, Georgoulias V.

Clin Cancer Res. 2004 Dec 15;10(24):8185-94.


E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells.

Yamauchi C, Fujii S, Kimura T, Kuwata T, Wada N, Mukai H, Matsumoto N, Fukayama M, Ochiai A.

Int J Cancer. 2011 May 1;128(9):2125-37. doi: 10.1002/ijc.25803.


Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours.

Gelardi T, Damiano V, Rosa R, Bianco R, Cozzolino R, Tortora G, Laccetti P, D'Alessio G, De Lorenzo C.

Br J Cancer. 2010 Feb 2;102(3):513-9. doi: 10.1038/sj.bjc.6605499. Epub 2010 Jan 5.


Targeting trastuzumab-resistant breast cancer cells with a lentivirus engineered to bind antibodies that recognize HER-2.

Zhang KX, Kim C, Chow E, Chen IS, Jia W, Rennie PS.

Breast Cancer Res Treat. 2011 Jan;125(1):89-97. doi: 10.1007/s10549-010-0828-9. Epub 2010 Mar 16.


Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients.

Rack B, Jückstock J, Günthner-Biller M, Andergassen U, Neugebauer J, Hepp P, Schoberth A, Mayr D, Zwingers T, Schindlbeck C, Friese K, Janni W.

Arch Gynecol Obstet. 2012 Feb;285(2):485-92. doi: 10.1007/s00404-011-1954-2. Epub 2011 Jun 30.


MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.

Fessler SP, Wotkowicz MT, Mahanta SK, Bamdad C.

Breast Cancer Res Treat. 2009 Nov;118(1):113-24. doi: 10.1007/s10549-009-0412-3. Epub 2009 May 5.


Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer.

Dokmanovic M, Hirsch DS, Shen Y, Wu WJ.

Mol Cancer Ther. 2009 Jun;8(6):1557-69. doi: 10.1158/1535-7163.MCT-09-0140. Epub 2009 Jun 9.


Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer.

Pályi-Krekk Z, Barok M, Isola J, Tammi M, Szöllosi J, Nagy P.

Eur J Cancer. 2007 Nov;43(16):2423-33.


Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.

Barok M, Tanner M, Köninki K, Isola J.

Cancer Lett. 2011 Jul 28;306(2):171-9. doi: 10.1016/j.canlet.2011.03.002. Epub 2011 Apr 1.


A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action.

Damiano V, Garofalo S, Rosa R, Bianco R, Caputo R, Gelardi T, Merola G, Racioppi L, Garbi C, Kandimalla ER, Agrawal S, Tortora G.

Clin Cancer Res. 2009 Nov 15;15(22):6921-30. doi: 10.1158/1078-0432.CCR-09-1599. Epub 2009 Nov 10.

Supplemental Content

Support Center